Test your drug on human tumor models.
For human-relevant results.
CanChip builds miniaturized human tumor systems that replace animal testing in oncology — delivering clinically relevant drug response data before Phase I begins.
Tumor-on-Chip • Human-relevant data • 3D microfluidics • Oncology validation • Fraunhofer-certified • No animal testing
From study design to data report
one integrated platform.
Study Design
We define the model, cell types, drug concentrations, and readouts based on your indication and compound.
Chip Fabrication
Custom microfluidic chips are designed and 3D-printed in-house, tailored to replicate the specific tumor microenvironment.
Cell Culture & Co-Culture
Human tumor cells are seeded and cultured under physiological flow conditions, including co-culture with relevant cell types.
Drug Testing
Your compound is applied under controlled, human-relevant conditions. Real-time imaging is available throughout.
Data Analysis & Report
Gene expression, biomarker readouts, and drug response profiles are analyzed and delivered in a structured report with go/no-go interpretation.
A growing library of
validated human tumor models.
Liver-on-Chip
Validated
~4× higher CYP3A4 expression compared to standard 2D culture, indicating markedly enhanced physiological relevance.
Our 3D liver model replicates hepatocellular microenvironments under physiological flow conditions – critical for accurate assessment of drug metabolism and hepatotoxicity.
Pancreas-on-Chip
Validated
~5× CA19-9 reduction under combination therapy – a clinically relevant response frequently missed in standard preclinical models.
Our pancreas model captures the complex tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) – one of the most treatment-resistant cancers.
CRC-on-Chip
Validated
Strong TYMS target suppression (0.35×) and RAC3 pathway downregulation under 5-FU – consistent with clinical response data.
Our colorectal cancer model reproduces clinically relevant drug responses under physiological exposure conditions, including the role of angiogenesis in tumor progression.
Prostate-on-Chip
Validated
Up to 66% PSA suppression under enzalutamide, dose-dependent, with pathway-consistent gene modulation.
Our AR-driven prostate cancer model reproduces hormone-sensitive tumor behavior, including response to androgen receptor antagonists.
Don’t see yours? Let’s talk
Tell us your indication — we respond with a study concept within 48 hours.
Choose the format that fits
your pipeline stage.
Pilot Study
Scope~10 chips
Typical duration4-6 Weeks
Suited forFirst signal generation, feasibility testing, internal go/no-go decision
Expanded Study
Scope20-50+ chips
Typical duration8-14 Weeks
Suited forStatistically robust data, dose-response profiling, investor/regulatory dossier
Strategic Partnership
ScopeRecurring programms
Typical durationOngoing
Suited forPipeline companies seeking a long-term validation partner with centralized data accumulation
What you receive
at the end of every study.
- Structured drug response report with go/no-go interpretation
- Gene expression analysis (qPCR-based, indication-specific markers)
- Biomarker readouts and dose-response profiles
- Cell viability and proliferation data
- Optional: real-time imaging data and flow cytometry analysis
- All raw data files for internal use and regulatory documentation
- Further read-outs on request
Tell us your indication. We design the study.
We respond with a study concept within 48 hours.